(April 17, 2020)
The Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer brings together women’s healthcare professionals from across the globe to discuss the latest findings in gynecologic oncology.
This year, the conference is being held virtually, through a series of high-level webinars that are free and open to the public.
Click through to register with the “Registration Link for Non-CE” option.
- 4/29 – Paradigm Changes in Front Line Ovarian Cancer
- 5/5 – Rare Tumors
- 5/7 – Molecular Testing and Patient Selection in Ovarian Cancer
- 5/12 – Surgical Innovations in Gynecologic Cancers
- 5/14 – Front Line Ovarian Cancer: Turning Up the Heat on Ovarian Cancer
- 5/22 – Genetic Discoveries and Pathologic Variations in Ovarian Cancer
- 5/28 – Developmental Therapeutics in Gynecologic Cancer
This year’s conference had many promising studies submitted, indicating further advancement in our understanding of these cancers:
- New evidence shows benefit of Niraparib maintenance therapy for patients with advanced ovarian cancer who were initially treated with platinum-based chemotherapy. This phase III trial showed an average increase of about 6 months for patients on Niraparib from the time of randomization in the trial to the time the patient started her second line of treatment.
- MEK inhibitor trametinib was associated with improved progression-free survival in a cohort of patients with low-grade serous carcinoma, compared to standard of care. This phase II–III trial was an international collaboration between teams in the United States and the United Kingdom.
- When used as a maintenance therapy, Olaparib with Bevacizumab improved median progression-free survival outcomes compared with using Bevacizumab alone. This was found in newly diagnosed patients with advanced high-grade serous ovarian cancer at a median follow-up of 2 years or longer.
- The tissue of the fallopian tubes has been thought to be the origin site of high-grade serous ovarian cancer. In aiming to find potential precancerous sites in healthy fallopian tissue of postmenopausal BRCA1 mutation carriers, researchers found that further study is needed to determine whether these changes are evidence of the earliest stages of cancer development in this population.